HELIOS Advanced: Human Oocyte Illumination to Enhance Development

Conditions

• IVF Outcomes

Eligibility Criteria

Sex

FEMALE

Age

18 Years - 48 Years

Healthy Volunteers

Accepted

Interventions

• Photobiomodulation — OTHER
  Photobiomodulation (PBM): also known as low-level light therapy (LLLT), involves the application of low-intensity red or near-infrared (NIR) light to modulate mitochondrial activity.

Study Details

Oocytes need a lot of energy to complete meiosis and fertilize successfully. As women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.

Key Dates

Start date

Mar 24, 2026

Status verified

Mar 2026

Primary completion

Jun 1, 2027

Completion

Jun 1, 2028

Study Design

Enrollment

270 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• No Intervention: No photobiomodulation
  Participants will receive the same treatment (IVF/ICSI cycles with PGT-A). Participant's resultant oocytes will be randomized to not receive PBM.
• Experimental: Photobiomodulation
  Participants will receive the same treatment (IVF/ICSI cycles with PGT-A). Participant's resultant oocytes will be randomized to receive PBM.

Primary Outcome Measure

Number of usable blastocysts [ Time Frame: Seven days post egg retrieval ]

Central Contacts

• Samuel Zev Williams, MD, PhD
  646-756-8282
  [email protected]
• Laura C Gemmell, MD, MSc
  646-756-8282
  [email protected]

Locations (1)

Find similar trials in New York, NY